RadNet (RDNT) Q3 2025 earnings summary

Executive summary

• Achieved record quarterly revenue of $522.9 million in Q3 2025, up 13.4% year-over-year, and nine-month revenue of $1.49 billion, up 10.4%, driven by advanced imaging growth, acquisitions, and technology rollouts.

• Adjusted EBITDA rose 15.2% to $84.9 million in Q3, with margin expansion to 16.2%; nine-month Adjusted EBITDA was $212.5 million.

• Net income attributable to common stockholders was $5.4 million for Q3, while net loss for the nine months was $18.1 million due to higher operating expenses and Digital Health investments.

• Major acquisitions of iCAD and See-Mode expanded AI and digital health capabilities, with integration ahead of plan and cost synergies realized.

• Growth supported by robust advanced imaging volumes, shift to ambulatory imaging, and increased adoption of AI-powered solutions in breast and thyroid imaging.

Financial highlights

• Total company revenue increased 13.4% year-over-year in Q3; nine-month revenue reached $1,492.5 million, up 10.3%.

• Adjusted EBITDA for Q3 was $84.9 million, margin up to 16.2%; nine-month Adjusted EBITDA was $212.5 million.

• Digital Health segment revenue grew 51.6% in Q3 to $24.8 million; nine-month growth was 38.2%.

• Advanced Imaging volumes: MRI up 14.8%, CT up 9.4%, PET/CT up 21.1% year-over-year in Q3.

• Cash balance at quarter-end was $804.7 million; interest expense decreased 16.2% year-over-year.

Outlook and guidance

• Raised 2025 full-year guidance: Imaging Center revenue to $1,900–$1,930 million, Digital Health revenue to $85–$95 million, and Adjusted EBITDA to $162–$167 million.

• Digital Health revenue guidance increased by $5M to reflect iCAD acquisition; adjusted EBITDA guidance held steady due to faster-than-expected cost synergies.

• 2026 Medicare reimbursement expected to provide a $4M–$5M revenue uplift, reversing a multi-year trend of annual cuts.

• Management expects continued growth in Imaging Center volumes and Digital Health expansion, with ongoing investments in AI and technology integration.

• Near-term net losses anticipated in Digital Health as integration of recent acquisitions continues.